Aeglea BioTherapeutics’ AEB1102 Secures Fast Track Designation

Aeglea BioTherapeutics received the FDA’s fast track designation for its candidate AEB1102, which aims to treat hyperargininemia secondary to Arginase I deficiency.

The designation for the Austin, Texas-based company’s lead investigational molecule will enable it to expedite development.